HomeComparePBMFF vs ABBV

PBMFF vs ABBV: Dividend Comparison 2026

PBMFF yields 4784.69% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBMFF wins by $40583540138285.46M in total portfolio value
10 years
PBMFF
PBMFF
● Live price
4784.69%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40583540138285.55M
Annual income
$38,980,900,320,915,210,000.00
Full PBMFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PBMFF vs ABBV

📍 PBMFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBMFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBMFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBMFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBMFF
Annual income on $10K today (after 15% tax)
$406,698.56/yr
After 10yr DRIP, annual income (after tax)
$33,133,765,272,777,930,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PBMFF beats the other by $33,133,765,272,777,910,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBMFF + ABBV for your $10,000?

PBMFF: 50%ABBV: 50%
100% ABBV50/50100% PBMFF
Portfolio after 10yr
$20291770069142.83M
Annual income
$19,490,450,160,457,617,000.00/yr
Blended yield
96.05%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PBMFF
No analyst data
Altman Z
-119.0
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBMFF buys
0
ABBV buys
0
No recent congressional trades found for PBMFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBMFFABBV
Forward yield4784.69%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$40583540138285.55M$102.3K
Annual income after 10y$38,980,900,320,915,210,000.00$24,771.77
Total dividends collected$40474947708927.02M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PBMFF vs ABBV ($10,000, DRIP)

YearPBMFF PortfolioPBMFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$489,169$478,468.90$11,550$430.00+$477.6KPBMFF
2$22,397,439$21,874,028.51$13,472$627.96+$22.38MPBMFF
3$959,983,960$936,018,700.38$15,906$926.08+$959.97MPBMFF
4$38,521,578,469$37,494,395,631.02$19,071$1,382.55+$38521.56MPBMFF
5$1,447,339,035,096$1,406,120,946,134.31$23,302$2,095.81+$1447339.01MPBMFF
6$50,923,424,492,455$49,374,771,724,902.77$29,150$3,237.93+$50923424.46MPBMFF
7$1,678,049,208,735,866$1,623,561,144,528,939.20$37,536$5,121.41+$1678049208.70MPBMFF
8$51,795,738,089,227,896$50,000,225,435,880,520.00$50,079$8,338.38+$51795738089.18MPBMFF
9$1,497,794,221,841,443,800$1,442,372,782,085,970,000.00$69,753$14,065.80+$1497794221841.37MPBMFF
10$40,583,540,138,285,556,000$38,980,900,320,915,210,000.00$102,337$24,771.77+$40583540138285.46MPBMFF

PBMFF vs ABBV: Complete Analysis 2026

PBMFFStock

Pacific Bay Minerals Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for zinc, silver, lead, copper, bismuth, molybdenum, and gold deposits. It holds 100% interests in the Haskins-Reed property located in the Cassiar Mining District of North Central British Columbia; the Weaver Lake property situated in the New Westminster Mining Division of British Columbia; and the Wheaton Creek property located in the Stikine Mining Division of British Columbia. The company also has an option to acquire a 100% interest in the Atlin Goldfields property located in Northwestern British Columbia. Pacific Bay Minerals Ltd. was founded in 1983 and is headquartered in Vancouver, Canada.

Full PBMFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PBMFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBMFF vs SCHDPBMFF vs JEPIPBMFF vs OPBMFF vs KOPBMFF vs MAINPBMFF vs JNJPBMFF vs MRKPBMFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.